Cerner (CERN) PT Raised to $49 at Morgan Stanley

Go back to Cerner (CERN) PT Raised to $49 at Morgan Stanley

SunTrust Upgrades Cerner (CERN) to Buy

April 10, 2019 6:44 AM EDT

SunTrust analyst Sandy Draper upgraded Cerner (NASDAQ: CERN) from Hold to Buy with a price target of $76.00 (from $60.00) following agreement with Starboard.

We see legs with strategy pivot.

For an analyst ratings summary and ratings history on... More

Cerner (CERN) PT Raised to $77 at Citi

April 10, 2019 6:26 AM EDT

Citi analyst Stephanie Demko raised the price target on Cerner (NASDAQ: CERN) to $77.00 (from $68.00) while maintaining a Buy rating following agreement with Starboard Value.

actions echo our Buy thesis on CERN as they believe it is a core HCIT asset with strong... More

Cerner (CERN) PT Raised to $71 at Baird

April 9, 2019 1:41 PM EDT

Baird analyst Matthew Gillmor raised the price target on Cerner (NASDAQ: CERN) to $71.00 (from $67.00) while maintaining a Outperform rating.

... More

Cerner settles with hedge fund Starboard: to add new directors, increase buybacks

April 9, 2019 11:15 AM EDT

(Reuters) - Healthcare information company Cerner Corp said on Tuesday it reached a settlement with activist hedge fund Starboard Value LP to add new directors to its board and buy back more of its shares, sending the stock up as much as 15.6 percent.

Cerner has agreed to improving operations and committing to hitting certain operating targets. Cerner said it hired consulting firm AlixPartners to review... More

Evercore ISI Upgrades Cerner (CERN) to In Line

April 9, 2019 9:28 AM EDT

Evercore ISI upgraded Cerner (NASDAQ: CERN) from Underperform to In Line with a price target of $64.00.

For an analyst ratings summary and ratings history on Cerner click here. For more ratings news on Cerner click here.

Shares of Cerner closed at $63.01 yesterday.

... More

Pre-Open Stock Movers 04/09: (PHAS) (CERN) (AVYA) Higher; (ZGNX) (ZSAN) (DARE) Lower (more...)

April 9, 2019 9:19 AM EDT

Today's Pre-Open Stock Movers

Zogenix, Inc. (NASDAQ: ZGNX) 27.4% LOWER; announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine hydrochloride) for the treatment of seizures associated with Dravet syndrome.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) 24.9% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PB2452, a novel reversal agent for the antiplatelet... More

Cerner (CERN) Announces Pact with Starboard Value on Board Refreshment, Operational Improvement Initiatives and Expanded Capital Returns

April 9, 2019 7:55 AM EDT

Cerner Corporation (NASDAQ: CERN) today announced that the Company has entered into a cooperation agreement with Starboard Value LP. The Cooperation Agreement includes a Board refreshment plan, operational improvement initiatives, commitments for operating margin targets, a new Finance and Strategy Committee of the Board and an expanded capital return program to drive the next phase of profitable growth and value creation.

The Companys Board of Directors has appointed four new directors, effective immediately: John Greisch, former President and Chief Executive Officer of Hill-Rom Holdings, Inc., R. Halsey... More